Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes"

Lung Cancer. 2019 Nov:137:159-160. doi: 10.1016/j.lungcan.2019.08.020. Epub 2019 Aug 26.

Authors

Jacqueline V Aredo¹, Sukhmani K Padda¹, Christian A Kunder², Summer S Han¹, Joel W Neal¹, Joseph B Shrager¹, Heather A Wakelee³

Affiliations

¹ Stanford Cancer Institute, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA, 94305, USA.
² Department of Pathology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA, 94305, USA.
³ Stanford Cancer Institute, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA, 94305, USA. Electronic address: hwakelee@stanford.edu.

PMID: 31492438
DOI: 10.1016/j.lungcan.2019.08.020

No abstract available

Publication types

Letter
Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung*
ErbB Receptors / genetics
Humans
Lung Neoplasms*
Mutation
Proto-Oncogene Proteins p21(ras)

Substances

KRAS protein, human
ErbB Receptors
Proto-Oncogene Proteins p21(ras)